ATE244570T1 - Immunmodulierende zusammensetzungen aus galle - Google Patents
Immunmodulierende zusammensetzungen aus galleInfo
- Publication number
- ATE244570T1 ATE244570T1 AT94926737T AT94926737T ATE244570T1 AT E244570 T1 ATE244570 T1 AT E244570T1 AT 94926737 T AT94926737 T AT 94926737T AT 94926737 T AT94926737 T AT 94926737T AT E244570 T1 ATE244570 T1 AT E244570T1
- Authority
- AT
- Austria
- Prior art keywords
- immunomodulator
- composition
- relates
- bil
- immunomodulating compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 230000002584 immunomodulator Effects 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 102000004388 Interleukin-4 Human genes 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102000004890 Interleukin-8 Human genes 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 231100001083 no cytotoxicity Toxicity 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000006433 tumor necrosis factor production Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11826993A | 1993-09-09 | 1993-09-09 | |
| US15530393A | 1993-11-22 | 1993-11-22 | |
| US23172694A | 1994-04-22 | 1994-04-22 | |
| PCT/CA1994/000494 WO1995007089A1 (en) | 1993-09-09 | 1994-09-09 | Immunomodulating compositions from bile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244570T1 true ATE244570T1 (de) | 2003-07-15 |
Family
ID=27382133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94926737T ATE244570T1 (de) | 1993-09-09 | 1994-09-09 | Immunmodulierende zusammensetzungen aus galle |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6280774B1 (de) |
| EP (1) | EP0717631B1 (de) |
| JP (1) | JP4708511B2 (de) |
| KR (1) | KR100260110B1 (de) |
| CN (1) | CN1132586C (de) |
| AT (1) | ATE244570T1 (de) |
| AU (1) | AU7648994A (de) |
| CA (1) | CA2171281C (de) |
| DE (1) | DE69432930T2 (de) |
| ES (1) | ES2207639T3 (de) |
| FI (1) | FI961109A (de) |
| HK (1) | HK1007922A1 (de) |
| NO (1) | NO960907L (de) |
| NZ (1) | NZ273258A (de) |
| WO (1) | WO1995007089A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028175A1 (en) * | 1995-03-16 | 1996-09-19 | Imutec Pharma Inc. | Immunomodulating compositions from bile for the treatment of immune system disorders |
| EP1629849B2 (de) | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmazeutische Zusammensetzungen enthaltend Exendine und deren Agonisten |
| CA2206047A1 (en) * | 1997-05-23 | 1998-11-23 | Romeo Rang (Deceased) | Immunomodulating compositions for the treatment of viral disorders |
| NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| AU2002214876A1 (en) | 2000-11-08 | 2002-05-21 | Lorus Therapeutics Inc. | Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
| ITRM20010688A1 (it) | 2001-11-21 | 2003-05-21 | Univ Roma | Composti immunoregolatori. |
| WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| JP4274469B2 (ja) * | 2004-01-20 | 2009-06-10 | Ｏｋｉセミコンダクタ株式会社 | データ取り込みクロック補正回路 |
| WO2006094384A1 (en) * | 2005-03-08 | 2006-09-14 | Genesense Technologies Inc. | Use of interleukin 17e for the treatment of cancer |
| GB0513431D0 (en) * | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
| CN101629951B (zh) * | 2009-08-20 | 2013-01-02 | 吴广印 | 一种人胎盘组织液抗炎作用检测方法 |
| US8338383B1 (en) | 2012-02-17 | 2012-12-25 | Gregory Jr Daniel Tyree | Use of immunomodulators for the treatment of cancer |
| US8236354B1 (en) * | 2012-02-17 | 2012-08-07 | ZOR Pharmaceuticals, LLC | Use of immunomodulators for the treatment of cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2046092B (en) | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
| US4562179A (en) | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
| US4585762A (en) | 1982-07-30 | 1986-04-29 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same |
| JPS5984824A (ja) | 1982-11-08 | 1984-05-16 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
| US4767610A (en) | 1984-10-19 | 1988-08-30 | The Regents Of The University Of California | Method for detecting abnormal cell masses in animals |
| US4916249A (en) | 1985-07-03 | 1990-04-10 | Hans Brachwitz | Glycero-3(2)-phospho-L-serine derivatives and salts thereof |
| CA1280369C (en) | 1985-12-04 | 1991-02-19 | Hansjorg Eibl | Pharmaceutical with anti-tumor effect |
| GB8706313D0 (en) * | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
| US5087721A (en) | 1987-10-23 | 1992-02-11 | The University Of Michigan | Radioiodinated phosphate esters |
| US4965391A (en) | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
| US5138067A (en) | 1987-12-17 | 1992-08-11 | Shionogi & Co. Ltd. | Lipid derivatives |
| EP0397774A1 (de) * | 1988-02-04 | 1990-11-22 | Board Of Regents, The University Of Texas System | Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten |
| EP0356765A3 (de) | 1988-08-19 | 1991-08-07 | Takeda Chemical Industries, Ltd. | Carbonsäurederivate, deren Herstellung und Verwendung |
| EP0378763A1 (de) | 1988-10-27 | 1990-07-25 | Takeda Chemical Industries, Ltd. | Lipide, ihre Herstellung und Verwendung |
| US5109118A (en) | 1989-07-06 | 1992-04-28 | Yutaka Mizushima | Modified biologically active proteins |
| GB8928580D0 (en) | 1989-12-19 | 1990-02-21 | Scras | 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives |
| US5369097A (en) | 1991-04-25 | 1994-11-29 | The University Of British Columbia | Phosphonates as anti-cancer agents |
-
1994
- 1994-09-09 US US08/612,921 patent/US6280774B1/en not_active Expired - Lifetime
- 1994-09-09 EP EP94926737A patent/EP0717631B1/de not_active Expired - Lifetime
- 1994-09-09 AT AT94926737T patent/ATE244570T1/de not_active IP Right Cessation
- 1994-09-09 CA CA002171281A patent/CA2171281C/en not_active Expired - Lifetime
- 1994-09-09 ES ES94926737T patent/ES2207639T3/es not_active Expired - Lifetime
- 1994-09-09 CN CN94194002A patent/CN1132586C/zh not_active Expired - Lifetime
- 1994-09-09 WO PCT/CA1994/000494 patent/WO1995007089A1/en active IP Right Grant
- 1994-09-09 NZ NZ273258A patent/NZ273258A/xx not_active IP Right Cessation
- 1994-09-09 KR KR1019960701198A patent/KR100260110B1/ko not_active IP Right Cessation
- 1994-09-09 DE DE69432930T patent/DE69432930T2/de not_active Expired - Lifetime
- 1994-09-09 JP JP50837095A patent/JP4708511B2/ja not_active Expired - Lifetime
- 1994-09-09 AU AU76489/94A patent/AU7648994A/en not_active Abandoned
-
1996
- 1996-03-06 NO NO960907A patent/NO960907L/no not_active Application Discontinuation
- 1996-03-08 FI FI961109A patent/FI961109A/fi unknown
-
1998
- 1998-06-27 HK HK98107139A patent/HK1007922A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI961109A (fi) | 1996-05-06 |
| DE69432930D1 (de) | 2003-08-14 |
| FI961109A0 (fi) | 1996-03-08 |
| HK1007922A1 (en) | 1999-04-30 |
| CA2171281C (en) | 1998-12-29 |
| CA2171281A1 (en) | 1995-03-16 |
| WO1995007089A1 (en) | 1995-03-16 |
| KR100260110B1 (ko) | 2000-07-01 |
| CN1132586C (zh) | 2003-12-31 |
| EP0717631A1 (de) | 1996-06-26 |
| DE69432930T2 (de) | 2004-05-06 |
| AU7648994A (en) | 1995-03-27 |
| EP0717631B1 (de) | 2003-07-09 |
| CN1136777A (zh) | 1996-11-27 |
| JP4708511B2 (ja) | 2011-06-22 |
| US6280774B1 (en) | 2001-08-28 |
| JPH09502706A (ja) | 1997-03-18 |
| NZ273258A (en) | 2000-01-28 |
| ES2207639T3 (es) | 2004-06-01 |
| NO960907L (no) | 1996-04-30 |
| NO960907D0 (no) | 1996-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE244570T1 (de) | Immunmodulierende zusammensetzungen aus galle | |
| JO1365B1 (en) | Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included. | |
| MX9602259A (es) | Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion. | |
| EP0759939A4 (de) | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen | |
| NO974257L (no) | Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer | |
| MY111402A (en) | Novel uses of il-4 and/or il-10, and antibodies against the same | |
| CA2193993A1 (en) | New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4 | |
| ES8603949A1 (es) | Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado | |
| DE3683430D1 (de) | Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung. | |
| HK1029330A1 (en) | N-hydroxyformamide derivatives | |
| Seckinger et al. | Modulation of the effects of interleukin‐1 on glycosaminoglycan synthesis by the urine‐derived interleukin‐1 inhibitor, but not by interleukin‐6 | |
| CA2094275A1 (en) | Methods and compositions for the treatment of cell proliferation disorders | |
| PT100651A (pt) | Muteinas da interleucina 6 (il-6) isentas de cisteina | |
| NO922456D0 (no) | Bcrf1-proteiner som inhibitorer av interferon-gamma | |
| JPS6463395A (en) | Oncostatin m and novel composition having antitumor activity | |
| Kapp et al. | Granulocyte-activating mediators (GRAM) II. Generation by human epidermal cells-relation to GM-CSF | |
| WO1988006625A3 (en) | Arginine-depleted human tumor necrosis factor | |
| Lee et al. | Effect of SK&F 86002 on cytokine production by human monocytes | |
| DK0793503T3 (da) | Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler | |
| CA2266743A1 (en) | Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses | |
| DE69131202D1 (de) | Die Verwendung von IL-4 und TNF zur Herstellung eines Medikaments zur Behandlung von Krebszellen | |
| UA27055C2 (uk) | Лікарський препарат імуhозаміhhої дії hа осhові клітиhhої суспеhзії та спосіб лікуваhhя сиhдрому hабутого імуhодефіциту (віл-іhфекції) з використаhhям цього препарату | |
| Sihvola et al. | The Effect of Gamma Interferon on Interleukin 1 Release of Human Monocytes: Dependence on the Activating Agent and Correlation to the mRNA Levels | |
| EP0426458A2 (de) | Menschlicher Monozytenwachstumsfaktor | |
| MX9602407A (es) | Composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |